A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Epoprostenol (Primary) ; Epoprostenol
- Indications Pulmonary hypertension
- Focus Pharmacodynamics
- Sponsors Aerogen
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 24 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.